SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), today announced that it has changed its name to Harbor BioSciences, Inc. and that its ticker symbol...
BOSTON, Nov. 16 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for...
- Company Provides Update on Progress of Lead Compounds - SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), will present results of its ongoing human...
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals (NASDAQ:HEPH) has retained Burrill LLC to provide exclusive strategic advisory services, with an initial focus on...
SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal...
SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal...
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today reported financial results for the fourth quarter and year ended December 31, 2008. For the quarter ended December 31...
The Wall Street Transcript has published an in-depth interview with Richard Hollis, Chairman, President and CEO of Hollis-Eden Pharmaceuticals (NASDAQ:HEPH) in which he talks at...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.